BioSpace News Archive

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it has executed its license agreement with the life science business of Merck KGaA, Darmstadt, Germany, to obtain a worldwide exclusive license for the clinical development and commercialization of radiolabeled folate derivatives for therapeutic and diagnostic applications against folate-receptor-positive malignant tumors.

Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, sleep problems and brain fog.

The Feinstein Institutes for Medical Research and Molecular Medicine announced that Peter Hotez, MD, PhD, a distinguished immunologist, pediatrician, and global health advocate, has been awarded the Anthony Cerami Award in Translational Medicine for his outstanding contributions to the field of molecular medicine and his dedication to addressing global health challenges.

Life science data can be highly disjointed and complex yet rich in potential insights. There are a variety of common insight-generation activities carried out with functional groups and through different channels

Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2024 at approximately 8:00 A.M. Eastern time on Monday, February 5, 2024.

The U.S. Food and Drug Administration, in collaboration with U.S. Customs and Border Protection, announced the seizure of approximately 1.4 million units of unauthorized e-cigarette products, including brands such as Elf Bar, which according to the 2023 National Youth Tobacco Survey, is the most commonly used brand among youth e-cigarette users.

People who live in neighborhoods with higher levels of poverty and unemployment are less likely to fill their heart-failure drug prescriptions than those living in wealthier areas, a new study shows.

USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk neuroblastoma.

QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is reinforcing its focus on qualitative and quantitative bioanalysis of biotherapeutics in Europe.

Median Technologies and PASREL-Imagerie, announce the signing of an agreement to deliver cutting-edge imaging biomarkers for the development of new oncology drugs in the era of precision medicine.